Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures

O. Devinsky, R. E. Faught, B. J. Wilder, Andres M Kanner, M. Kamin, L. D. Kramer, A. Rosenberg

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The efficacy and safety of felbamate monotherapy were evaluated in 52 patients with refractory partial seizures with or without secondary generalization in a double-blind, randomized, placebo-controlled trial. Each patient completed a routine evaluation for epilepsy surgery and was randomized to receive either felbamate, titrated to a maximum daily dose of 3600 mg over 2 days, or placebo during the 10-day, inpatient, treatment phase. An intent-to-treat analysis was performed on the data of all 52 patients who received study medication, while a separate efficacy analysis also was performed on the data of 43 evaluable patients, which excluded protocol violators. The endpoint of the trial was completing 10 days of treatment or the occurrence of a fourth seizure. The primary efficacy variable was the average daily seizure frequency during the treatment phase for each patient. For the intent-to-treat analysis based on all 52 patients who received study medications, the mean rank of the daily seizure frequency for patients treated with felbamate was 21.6 compared to 29.6 for patients treated with placebo (P = 0.065). In the analysis based on the 43 evaluable patients, the mean rank of the daily seizure frequency for felbamate-treated patients was 17.0 compared to 25.4 for placebo-treated patients. This difference was statistically significant (P = 0.032) in favor of felbamate. Seizure frequency was decreased by 89.5% compared to baseline in nine patients who completed 10 days of felbamate therapy. This study permitted the rapid determination of the anticonvulsant activity of felbamate and demonstrated that felbamate is effective as monotherapy for the treatment of partial seizures.

Original languageEnglish (US)
Pages (from-to)241-246
Number of pages6
JournalEpilepsy Research
Volume20
Issue number3
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

felbamate
Seizures
Placebos

Keywords

  • Felbamate
  • Monotherapy
  • Partial seizures
  • Presurgical evaluation of partial seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. / Devinsky, O.; Faught, R. E.; Wilder, B. J.; Kanner, Andres M; Kamin, M.; Kramer, L. D.; Rosenberg, A.

In: Epilepsy Research, Vol. 20, No. 3, 1995, p. 241-246.

Research output: Contribution to journalArticle

Devinsky, O. ; Faught, R. E. ; Wilder, B. J. ; Kanner, Andres M ; Kamin, M. ; Kramer, L. D. ; Rosenberg, A. / Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. In: Epilepsy Research. 1995 ; Vol. 20, No. 3. pp. 241-246.
@article{305ca7c4a91646bda9800d78cf45181f,
title = "Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures",
abstract = "The efficacy and safety of felbamate monotherapy were evaluated in 52 patients with refractory partial seizures with or without secondary generalization in a double-blind, randomized, placebo-controlled trial. Each patient completed a routine evaluation for epilepsy surgery and was randomized to receive either felbamate, titrated to a maximum daily dose of 3600 mg over 2 days, or placebo during the 10-day, inpatient, treatment phase. An intent-to-treat analysis was performed on the data of all 52 patients who received study medication, while a separate efficacy analysis also was performed on the data of 43 evaluable patients, which excluded protocol violators. The endpoint of the trial was completing 10 days of treatment or the occurrence of a fourth seizure. The primary efficacy variable was the average daily seizure frequency during the treatment phase for each patient. For the intent-to-treat analysis based on all 52 patients who received study medications, the mean rank of the daily seizure frequency for patients treated with felbamate was 21.6 compared to 29.6 for patients treated with placebo (P = 0.065). In the analysis based on the 43 evaluable patients, the mean rank of the daily seizure frequency for felbamate-treated patients was 17.0 compared to 25.4 for placebo-treated patients. This difference was statistically significant (P = 0.032) in favor of felbamate. Seizure frequency was decreased by 89.5{\%} compared to baseline in nine patients who completed 10 days of felbamate therapy. This study permitted the rapid determination of the anticonvulsant activity of felbamate and demonstrated that felbamate is effective as monotherapy for the treatment of partial seizures.",
keywords = "Felbamate, Monotherapy, Partial seizures, Presurgical evaluation of partial seizures",
author = "O. Devinsky and Faught, {R. E.} and Wilder, {B. J.} and Kanner, {Andres M} and M. Kamin and Kramer, {L. D.} and A. Rosenberg",
year = "1995",
doi = "10.1016/0920-1211(94)00084-A",
language = "English (US)",
volume = "20",
pages = "241--246",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures

AU - Devinsky, O.

AU - Faught, R. E.

AU - Wilder, B. J.

AU - Kanner, Andres M

AU - Kamin, M.

AU - Kramer, L. D.

AU - Rosenberg, A.

PY - 1995

Y1 - 1995

N2 - The efficacy and safety of felbamate monotherapy were evaluated in 52 patients with refractory partial seizures with or without secondary generalization in a double-blind, randomized, placebo-controlled trial. Each patient completed a routine evaluation for epilepsy surgery and was randomized to receive either felbamate, titrated to a maximum daily dose of 3600 mg over 2 days, or placebo during the 10-day, inpatient, treatment phase. An intent-to-treat analysis was performed on the data of all 52 patients who received study medication, while a separate efficacy analysis also was performed on the data of 43 evaluable patients, which excluded protocol violators. The endpoint of the trial was completing 10 days of treatment or the occurrence of a fourth seizure. The primary efficacy variable was the average daily seizure frequency during the treatment phase for each patient. For the intent-to-treat analysis based on all 52 patients who received study medications, the mean rank of the daily seizure frequency for patients treated with felbamate was 21.6 compared to 29.6 for patients treated with placebo (P = 0.065). In the analysis based on the 43 evaluable patients, the mean rank of the daily seizure frequency for felbamate-treated patients was 17.0 compared to 25.4 for placebo-treated patients. This difference was statistically significant (P = 0.032) in favor of felbamate. Seizure frequency was decreased by 89.5% compared to baseline in nine patients who completed 10 days of felbamate therapy. This study permitted the rapid determination of the anticonvulsant activity of felbamate and demonstrated that felbamate is effective as monotherapy for the treatment of partial seizures.

AB - The efficacy and safety of felbamate monotherapy were evaluated in 52 patients with refractory partial seizures with or without secondary generalization in a double-blind, randomized, placebo-controlled trial. Each patient completed a routine evaluation for epilepsy surgery and was randomized to receive either felbamate, titrated to a maximum daily dose of 3600 mg over 2 days, or placebo during the 10-day, inpatient, treatment phase. An intent-to-treat analysis was performed on the data of all 52 patients who received study medication, while a separate efficacy analysis also was performed on the data of 43 evaluable patients, which excluded protocol violators. The endpoint of the trial was completing 10 days of treatment or the occurrence of a fourth seizure. The primary efficacy variable was the average daily seizure frequency during the treatment phase for each patient. For the intent-to-treat analysis based on all 52 patients who received study medications, the mean rank of the daily seizure frequency for patients treated with felbamate was 21.6 compared to 29.6 for patients treated with placebo (P = 0.065). In the analysis based on the 43 evaluable patients, the mean rank of the daily seizure frequency for felbamate-treated patients was 17.0 compared to 25.4 for placebo-treated patients. This difference was statistically significant (P = 0.032) in favor of felbamate. Seizure frequency was decreased by 89.5% compared to baseline in nine patients who completed 10 days of felbamate therapy. This study permitted the rapid determination of the anticonvulsant activity of felbamate and demonstrated that felbamate is effective as monotherapy for the treatment of partial seizures.

KW - Felbamate

KW - Monotherapy

KW - Partial seizures

KW - Presurgical evaluation of partial seizures

UR - http://www.scopus.com/inward/record.url?scp=0028911352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028911352&partnerID=8YFLogxK

U2 - 10.1016/0920-1211(94)00084-A

DO - 10.1016/0920-1211(94)00084-A

M3 - Article

C2 - 7796796

AN - SCOPUS:0028911352

VL - 20

SP - 241

EP - 246

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 3

ER -